Repair, restore, remember
Repairing the synapses that hold memory together.
We develop peptide therapeutics that restore the synaptic connections lost in Alzheimer's disease and related dementias. Built on neuroscience that defined how memory falls apart, and how to put it back together.
A new class of therapeutics built to repair the synapse.
EngramBio engineers peptides that restore synaptic function directly. Restoring synaptic function is the most upstream, most reversible step in cognitive decline. Our lead program is built on more than a decade of original neuroscience that defined how synapses fail in dementia and identified the protective biology our peptide chemistry is designed to mimic. Every candidate we advance survives both rigorous computational triage and experimental validation.
An integrated discovery engine for synapse-repair therapeutics.
Three disciplines, one decision at a time. Chemistry-aware modeling narrows a vast peptide design space. Physics-based simulation ranks candidates by binding fidelity and brain stability. Human iPSC-derived neuron assays then test every claim before a molecule moves forward.
Chemistry-Aware Peptide Design
We design lead molecules using structure-prediction tools that natively model drug-like properties. Candidates are then refined under physics-based molecular dynamics and free-energy calculations and ranked across binding, brain stability, and clinical translatability simultaneously. The result is a pipeline that converges on molecules with the trade-offs already engineered in.
Neuroscience-Led Wet Lab Validation
Every lead candidate is validated by our neuroscience team in disease-relevant models such as human iPSC-derived neurons, using methods such as electrophysiology and multi-electrode array recording to assess synaptic plasticity and network connectivity, with follow-up behavioral studies. Every computational claim is checked against experimental measurements before a molecule advances.
Diversified Synapse Repair Pipeline
We test therapeutics across a range of patient-relevant neuronal models, identifying candidates that restore synaptic function across the molecular diversity of real disease.
NIH NIA Startup Challenge Finalist
Selected as a finalist among top innovators nationwide for developing breakthrough technologies to advance healthy aging and address critical challenges in aging research.
NIH NIA Startup Challenge Winner
Awarded winner by the National Institute on Aging for our innovative approach to improving healthy aging outcomes, recognizing our technology's potential to transform aging care and research.
NVIDIA Inception
NVIDIA Inception is a program for early-stage startups that are using AI to solve real-world problems.
Leadership Team
Kristeen A. Pareja-Navarro, PhD
Chief Executive Officer, Co-founder
Dr. Pareja-Navarro is the CEO and co-founder of EngramBio, where she leads the development of therapeutics designed to r...
Tara E. Tracy, PhD.
Co-founder and Chair of Scientific Advisory Board
Dr. Tracy is the co-founder and the Chair of Scientific Advisory Board of EngramBio. She is also an Associate Professor ...
Ready to Transform Drug Discovery?
Join us in accelerating the development of life-changing neurological therapeutics.
Whether you're a pharmaceutical partner, investor, or research collaborator, let's discuss how we can work together to bring hope to patients worldwide.
Get in touchEngramBio
Synapse-repair therapeutics for Alzheimer's disease and related dementias.
Location
Moraga, CA
© 2026 EngramBio. All rights reserved.